HUT62194A - Process for producing pharmaceutical composition with tenidap content, reducing the concentration of total serum cholesterol, ldl cholesterol and triglycerides - Google Patents

Process for producing pharmaceutical composition with tenidap content, reducing the concentration of total serum cholesterol, ldl cholesterol and triglycerides

Info

Publication number
HUT62194A
HUT62194A HU9200395A HU9200395A HUT62194A HU T62194 A HUT62194 A HU T62194A HU 9200395 A HU9200395 A HU 9200395A HU 9200395 A HU9200395 A HU 9200395A HU T62194 A HUT62194 A HU T62194A
Authority
HU
Hungary
Prior art keywords
tenidap
triglycerides
cholesterol
total serum
concentration
Prior art date
Application number
HU9200395A
Other languages
English (en)
Other versions
HU9200395D0 (en
Inventor
Leland David Loose
Naitee Ting
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HU9200395D0 publication Critical patent/HU9200395D0/hu
Publication of HUT62194A publication Critical patent/HUT62194A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9200395A 1991-02-08 1992-02-07 Process for producing pharmaceutical composition with tenidap content, reducing the concentration of total serum cholesterol, ldl cholesterol and triglycerides HUT62194A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65270991A 1991-02-08 1991-02-08
US07/727,786 US5122534A (en) 1991-02-08 1991-07-10 Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides

Publications (2)

Publication Number Publication Date
HU9200395D0 HU9200395D0 (en) 1992-04-28
HUT62194A true HUT62194A (en) 1993-04-28

Family

ID=27096345

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9200395A HUT62194A (en) 1991-02-08 1992-02-07 Process for producing pharmaceutical composition with tenidap content, reducing the concentration of total serum cholesterol, ldl cholesterol and triglycerides

Country Status (17)

Country Link
US (1) US5122534A (hu)
EP (1) EP0498588B1 (hu)
JP (1) JPH0558893A (hu)
KR (1) KR940011245B1 (hu)
AT (1) ATE121620T1 (hu)
AU (1) AU630580B2 (hu)
CA (1) CA2060789C (hu)
DE (1) DE69202162T2 (hu)
DK (1) DK0498588T3 (hu)
HK (1) HK219096A (hu)
HU (1) HUT62194A (hu)
IE (1) IE65596B1 (hu)
MX (1) MX9200544A (hu)
MY (1) MY106885A (hu)
NZ (1) NZ241555A (hu)
PT (1) PT100095A (hu)
TW (1) TW206153B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513716A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Substituierte 2-Phenylindol-Derivate
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
US7780950B2 (en) * 2002-01-02 2010-08-24 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
ES2429528T3 (es) * 2001-01-02 2013-11-15 The Cleveland Clinic Foundation Mieloperoxidasa, un indicador de riesgo para enfermedad cardiovascular
US20060004088A1 (en) * 2002-10-22 2006-01-05 Oct Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
EP2306192B1 (en) * 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
RO105052B1 (en) * 1987-02-02 1994-12-01 Pfizer Producing process for the crystalline sodium salt, anhydre, of 5-chlorine-3-(2-tenoil)-2-oxindol-1-carboxamide
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

Also Published As

Publication number Publication date
DE69202162D1 (de) 1995-06-01
ATE121620T1 (de) 1995-05-15
EP0498588A1 (en) 1992-08-12
KR940011245B1 (ko) 1994-12-03
DE69202162T2 (de) 1995-08-31
AU1083192A (en) 1992-08-20
TW206153B (hu) 1993-05-21
MX9200544A (es) 1992-08-01
NZ241555A (en) 1997-02-24
AU630580B2 (en) 1992-10-29
KR920016094A (ko) 1992-09-24
JPH0558893A (ja) 1993-03-09
IE920405A1 (en) 1992-08-12
HU9200395D0 (en) 1992-04-28
CA2060789A1 (en) 1992-08-09
PT100095A (pt) 1993-04-30
HK219096A (en) 1997-01-03
CA2060789C (en) 1995-10-17
MY106885A (en) 1995-08-30
DK0498588T3 (da) 1995-07-10
IE65596B1 (en) 1995-11-01
US5122534A (en) 1992-06-16
EP0498588B1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
HUT62194A (en) Process for producing pharmaceutical composition with tenidap content, reducing the concentration of total serum cholesterol, ldl cholesterol and triglycerides
AU562938B2 (en) 7, 10, 13, 16 docosatetraenoic acid composition
GR3006068T3 (hu)
EP0334507A3 (en) Skin improving composition containing gamma-linolenic acid or dihomo-gamma-linolenic acid
EP0658763A3 (de) Verfahren zur quantitativen Bestimmung elektrochemisch reduzierbarer oder oxidierbarer Stoffe, insbesondere von Peroxiessigsäure im Gemisch mit anderen oxidierenden Stoffen.
AU554413B2 (en) Linoleic acid and essential fatty acid compositions as
NO881270D0 (no) Framgangsmaate for aa redusere carboninnholdet i halvledere.
ATE122675T1 (de) Stabile salze von 5,10- methylentetrahydrofolsäure.
DE68911501D1 (de) Analgetische antacide Brausezusammensetzung mit reduziertem Natriumgehalt.
ATE22804T1 (de) Pharmazeutische zusammensetzung.
DE68906853D1 (de) Flussmittelzusammensetzung und verfahren zur herabsetzung des zinngehalts in blei-zinn-lotverbindungen.
FR2671697B1 (fr) Procede de fabrication d'une composition a teneur elevee en alpha-lactalbumine.
HU906417D0 (en) Process for producing 3-(1-pyroglutamyl)-1-thiazolidine-4-carboxylic acid and its derivatives
ES2059403T3 (es) Composicion util en el tratamiento de deficiencias de estrogenos.
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.
DK0610697T3 (da) Imidazolyl-substituerede phenyleddikesyreprolinamider.
AU7358691A (en) Tenidap as an inhibitor of the release of elastage by neutrophils
RU97100954A (ru) Композиция, для изготовления древесно-полимерных материалов (варианты)
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
KR910012273A (ko) 용선예비처리용 탈인제
DE59503261D1 (de) Verfahren zur Herstellung von Retinal durch Oxidation von Retinol mit Sauerstoff in Gegenwart von 4-Hydroxy-2,2,6,6-tetramethyl-piperidin-1-oxyl und Kupfer(I)-chlorid
RU96122479A (ru) Способ внепечной обработки стали
DE60028593D1 (de) Perkutane absorptionsbeschleuniger für die elektroporation
DK346387A (da) Fremgangsmaade til at reducere alkaliindholdet i cementklinker
NO180570C (no) Fremgangsmåte for å redusere innholdet av metallkarbonyl i gass-strömmer

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal